Licensing status

Publication and
contact information



IL-15; IL-15 receptor a-chain (IL-15RA); apolipoprotein A-1 (APOA1)

Mouse studies suggest a triple fusion protein of APOA1, IL-15 and IL-15RA's sushi domain could prevent cancer metastasis. In a mouse model of metastatic melanoma or metastatic colorectal cancer, vector-induced expression of the triple fusion protein led to fewer metastatic lesions than vector-induced expression of an APOA1 and IL-15 fusion protein plus the IL-15RA sushi domain. In the mouse model of metastatic melanoma, 50 mg of the recombinant triple fusion protein decreased lung metastases compared with saline. Ongoing work includes exploring the synergy of the triple fusion protein with other cancer therapeutics.
Digna Biotech S.L. has the triple fusion protein in preclinical development.

SciBX 5(46); doi:10.1038/scibx.2012.1203
Published online Nov. 29, 2012

Patent applications filed; exclusively licensed to Digna Biotech

Ochoa, M.C. et al. Cancer Res.; published online Nov. 13, 2012;
Contact: Ignacio Melero, University of Navarra, Navarra, Spain